Pycnogenol for Blood Pressure and Heart Health

The cardiovascular claim best supported by the evidence is not “Pycnogenol lowers blood pressure” but the more specific “Pycnogenol improves the function of the artery lining.” The extract appears to boost nitric oxide, the molecule blood vessels use to relax, which improves endothelial function — and this was shown in an independent, well-designed Swiss trial in people with coronary artery disease, not only in manufacturer-linked studies. Blood pressure itself moves only modestly (a few mmHg in meta-analyses), and there are supporting signals for platelets, cholesterol, and cardiovascular risk factors in diabetes. This page separates the well-supported endothelial story from the more modest blood-pressure story, and keeps the honest caveats front and center.

The Endothelium: The Core of the Story
Endothelial Function Trials
Coronary Artery Disease: The Independent Trial
Blood Pressure: What the Meta-Analyses Show
Platelets and the Smoker Studies
Cholesterol, Blood Sugar, and Diabetes
Erectile Function: Endothelium Below the Belt
Practical Use and Expectations
Cautions and the Evidence Caveat
Key Research Papers
External Resources
Connections
Featured Videos

The Endothelium: The Core of the Story

The endothelium is the single layer of cells lining every blood vessel. Far from being passive plumbing, it is an active organ: it releases nitric oxide, a gas that signals the vessel wall to relax and widen, keeps blood flowing smoothly, discourages clots, and calms inflammation. When the endothelium works poorly — a state called endothelial dysfunction — vessels stay too constricted, blood pressure rises, and the earliest steps of atherosclerosis begin. Endothelial dysfunction is one of the earliest measurable warning signs of cardiovascular disease, often present years before a heart attack.

Pycnogenol's central cardiovascular mechanism is that its procyanidins stimulate endothelial nitric oxide synthase (eNOS), the enzyme that makes nitric oxide, so the endothelium produces more of it. Fitzpatrick and colleagues (1998) showed this endothelium-dependent, nitric-oxide-mediated relaxation of blood vessels in the laboratory. Because so many cardiovascular outcomes trace back to endothelial health, an agent that improves it could, in principle, help blood pressure, arterial flow, and clotting all at once — the same “one mechanism, many effects” theme seen across Pycnogenol's uses.

Back to Table of Contents

Endothelial Function Trials

Several human trials have measured endothelial function directly, usually with flow-mediated dilation (FMD) — an ultrasound test of how much an artery widens when blood flow surges, a standard proxy for nitric-oxide availability:

Liu and colleagues (2004) reported that Pycnogenol improved endothelial function in hypertensive patients.
Nishioka and colleagues (2007) reported that the extract augmented endothelium-dependent vasodilation in humans, tying the clinical effect to nitric oxide.
Hu and colleagues (2015) found improved endothelial function in people with borderline hypertension, hyperlipidemia, and hyperglycemia.

The direction is consistent: across different populations, Pycnogenol tends to improve this measure of arterial health. That consistency, and the fact that the effect is mechanistically expected, make endothelial function the most credible cardiovascular benefit — especially once an independent trial is added to the picture.

Back to Table of Contents

Coronary Artery Disease: The Independent Trial

Most Pycnogenol research comes from a small circle of investigators, often with manufacturer involvement, so an independent trial carries extra weight. Enseleit and colleagues (2012), based at a Swiss university hospital, ran a double-blind, randomized, placebo-controlled, cross-over study in patients with stable coronary artery disease and published it in the European Heart Journal. Pycnogenol significantly improved flow-mediated dilation — i.e., endothelial function — compared with placebo.

This is arguably the highest-quality piece of cardiovascular evidence for the extract: an independent group, a rigorous design, a hard physiological endpoint, and a respected journal. It is important to read it precisely, though. It demonstrated that Pycnogenol improves the function of the artery lining in people who already have coronary disease. It did not show that Pycnogenol prevents heart attacks, reduces deaths, or replaces any cardiac medication — those questions were not what the trial tested, and no study has answered them. Improved endothelial function is a promising surrogate marker, not a proven outcome.

Back to Table of Contents

Blood Pressure: What the Meta-Analyses Show

Because better endothelial function should relax arteries, several trials looked at blood pressure, and two systematic reviews pooled them. Pourmasoumi and colleagues (2020) and Fogacci and colleagues (2020) each meta-analyzed randomized, placebo-controlled trials of Pycnogenol on blood pressure. Both found modest reductions — on the order of a few millimeters of mercury — with the reviews differing somewhat on exactly which numbers reached statistical significance (systolic, diastolic, or both).

The honest summary: Pycnogenol produces a small, real, but clinically minor blood-pressure effect. A drop of a couple of mmHg is not nothing at a population level, but it is far weaker than a proper antihypertensive medication and should not be relied on to control diagnosed hypertension. It might be a marginal helper alongside lifestyle change in someone with borderline readings — and if you already take blood-pressure drugs, the additive effect is a reason to monitor, not to stop your medication.

Back to Table of Contents

Platelets and the Smoker Studies

Platelets are the blood cells that clump to form clots; overactive platelets contribute to heart attacks and strokes. Pütter and colleagues (1999) studied smokers, whose platelets are abnormally sticky, and found that Pycnogenol reduced smoking-induced platelet aggregation. Notably, in that study a single dose of the extract was comparable to aspirin for this specific measure, while having less effect on prolonging bleeding time.

This antiplatelet signal is a double-edged sword. On one hand it fits the cardiovascular-protective theme and may partly explain the flight-thrombosis findings on the Circulation & Veins page. On the other hand, it is precisely why Pycnogenol warrants caution alongside blood thinners and before surgery — a mild antiplatelet effect is helpful until it stacks on top of aspirin, clopidogrel, or an anticoagulant.

Back to Table of Contents

Cholesterol, Blood Sugar, and Diabetes

Cardiovascular risk is more than blood pressure, and Pycnogenol has been tested on several other risk factors, especially in type 2 diabetes:

Lipids. Devaraj and colleagues (2002) reported that a polyphenol-rich pine bark extract raised plasma antioxidant capacity and improved the lipoprotein profile — lowering LDL (“bad”) cholesterol and, in their data, nudging HDL (“good”) cholesterol up.
Cardiovascular risk factors in diabetes. Zibadi and colleagues (2008) found that Pycnogenol supplementation reduced several cardiovascular risk factors in people with type 2 diabetes.
Blood sugar. Liu and colleagues (2004) reported an antidiabetic effect — lower fasting glucose — in patients with type 2 diabetes, plausibly through the same microvascular and antioxidant mechanisms, and consistent with the retinal-microcirculation benefits in early diabetic retinopathy.

These are supportive signals, mostly from small studies. They suggest Pycnogenol touches several cardiovascular risk factors gently rather than powerfully — a reasonable adjunct picture, not a replacement for statins, blood-pressure medication, or diabetes therapy.

Back to Table of Contents

Erectile Function: Endothelium Below the Belt

Erections are a nitric-oxide and endothelial event, so it is logical that the extract has been studied there too, usually combined with the amino acid L-arginine (a nitric-oxide precursor) in a product called Prelox. Stanislavov and colleagues (2008) reported improved erectile function with this combination in a randomized, placebo-controlled cross-over trial. Because the studied product pairs Pycnogenol with arginine, the benefit cannot be attributed to Pycnogenol alone, and this remains a modest, industry-linked evidence base — but it is a neat illustration that the through-line of Pycnogenol's cardiovascular story is endothelial nitric oxide. For the condition itself, see Erectile Dysfunction.

Back to Table of Contents

Practical Use and Expectations

Cardiovascular trials have generally used Pycnogenol at roughly 100–200 mg per day (sometimes divided), for several weeks to a few months. As with the other uses, effects build gradually and are best measured over 8–12 weeks.

Set expectations correctly. The realistic benefit is modest support of vascular health: somewhat better endothelial function, a small blood-pressure nudge, gentle effects on lipids and platelets. Pycnogenol is not a treatment for diagnosed hypertension, high cholesterol, coronary disease, or diabetes, and it must never replace prescribed cardiovascular medication. If you have any of these conditions, treat Pycnogenol strictly as a possible add-on to discuss with your clinician — and keep taking your prescribed therapy.

Back to Table of Contents

Cautions and the Evidence Caveat

Interactions with cardiovascular drugs. Because Pycnogenol can lower blood pressure and reduce platelet stickiness, it may add to the effect of antihypertensives, anticoagulants, and antiplatelet drugs. Monitor blood pressure, watch for easy bruising or bleeding, and coordinate with your clinician.
Stop before surgery. Discontinue at least a week or two before any procedure because of the antiplatelet effect.
Surrogate markers, not outcomes. Improved endothelial function and small blood-pressure changes are promising signs, not proof of fewer heart attacks or longer life. No trial has shown Pycnogenol reduces cardiovascular events.
Evidence quality. The 2020 Cochrane review judged the overall evidence low quality; the Enseleit (2012) coronary trial is the standout independent exception. Weight the independent, blinded studies most heavily.
Not for self-managing diagnosed disease. Diabetes, hypertension, and coronary disease need real medical management; use this only as an adjunct.

Back to Table of Contents

Key Research Papers

Enseleit F et al. (2012). Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. European Heart Journal. — PubMed
Liu X et al. (2004). Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sciences. — PubMed
Nishioka K et al. (2007). Pycnogenol, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertension Research. — PubMed
Hu S et al. (2015). Effects of Pycnogenol on endothelial dysfunction in borderline hypertensive, hyperlipidemic, and hyperglycemic individuals: the borderline study. International Angiology. — PubMed
Fitzpatrick DF, Bing B, Rohdewald P (1998). Endothelium-dependent vascular effects of Pycnogenol. Journal of Cardiovascular Pharmacology. — PubMed
Pourmasoumi M et al. (2020). Effect of pycnogenol supplementation on blood pressure: a systematic review and meta-analysis of clinical trials. Phytotherapy Research. — PubMed
Fogacci F et al. (2020). Effect of Pycnogenol on blood pressure: findings from a PRISMA-compliant systematic review and meta-analysis. Angiology. — PubMed
Pütter M et al. (1999). Inhibition of smoking-induced platelet aggregation by aspirin and Pycnogenol. Thrombosis Research. — PubMed
Zibadi S et al. (2008). Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. Nutrition Research. — PubMed
Liu X et al. (2004). Antidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes type II. Life Sciences. — PubMed
Devaraj S et al. (2002). Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids. — PubMed
Stanislavov R et al. (2008). Improvement of erectile function with Prelox: a randomized, double-blind, placebo-controlled, crossover trial. International Journal of Impotence Research. — PubMed
Robertson NU et al. (2020). Pine bark (Pinus spp.) extract for treating chronic disorders. Cochrane Database of Systematic Reviews. — PubMed